Kevin M. Klemz Sells 2,268 Shares of Silk Road Medical, Inc (NASDAQ:SILK) Stock

Silk Road Medical, Inc (NASDAQ:SILK) EVP Kevin M. Klemz sold 2,268 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $27.10, for a total transaction of $61,462.80. Following the completion of the transaction, the executive vice president now directly owns 162,926 shares of the company’s stock, valued at $4,415,294.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Silk Road Medical Stock Performance

NASDAQ SILK opened at $27.21 on Friday. Silk Road Medical, Inc has a 1 year low of $6.08 and a 1 year high of $27.25. The company has a current ratio of 7.63, a quick ratio of 6.69 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $1.11 billion, a P/E ratio of -19.86 and a beta of 1.52. The firm’s fifty day moving average price is $26.81 and its two-hundred day moving average price is $21.53.

Silk Road Medical (NASDAQ:SILK) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). The company had revenue of $51.20 million for the quarter, compared to the consensus estimate of $49.74 million. Silk Road Medical had a negative return on equity of 37.30% and a negative net margin of 29.53%. The company’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.35) earnings per share. As a group, research analysts anticipate that Silk Road Medical, Inc will post -1.44 EPS for the current year.

Institutional Trading of Silk Road Medical

Several hedge funds have recently added to or reduced their stakes in the company. Wasatch Advisors LP increased its position in Silk Road Medical by 12.4% during the 1st quarter. Wasatch Advisors LP now owns 4,549,742 shares of the company’s stock worth $83,351,000 after buying an additional 500,581 shares during the period. Capital World Investors raised its stake in Silk Road Medical by 4.9% in the 1st quarter. Capital World Investors now owns 3,111,730 shares of the company’s stock worth $57,007,000 after purchasing an additional 145,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Silk Road Medical by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 2,922,495 shares of the company’s stock worth $53,540,000 after purchasing an additional 30,726 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Silk Road Medical by 707.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,010,983 shares of the company’s stock valued at $24,675,000 after purchasing an additional 1,762,048 shares during the period. Finally, Magnetar Financial LLC acquired a new position in shares of Silk Road Medical during the 2nd quarter worth approximately $53,279,000.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Piper Sandler upped their price objective on Silk Road Medical from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 1st. Stifel Nicolaus reaffirmed a “hold” rating and set a $27.50 price target (up from $23.00) on shares of Silk Road Medical in a research note on Wednesday, July 17th. Argus lowered shares of Silk Road Medical from a “buy” rating to a “sell” rating in a research report on Thursday, July 11th. JPMorgan Chase & Co. raised their target price on shares of Silk Road Medical from $19.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, May 1st. Finally, Lake Street Capital reissued a “hold” rating and set a $27.50 price target (down from $28.00) on shares of Silk Road Medical in a research report on Tuesday, June 18th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $21.50.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.